UK markets close in 5 hours 4 minutes

Hutchison China MediTech Limited (HCM.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
273.60+5.60 (+2.09%)
As of 09:45AM BST. Market open.

Hutchison China MediTech Limited

Cheung Kong Center
48th floor 2 Queen's Road Central
Hong Kong
Hong Kong
852 2121 8200
https://www.hutch-med.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees1,988

Key executives

NameTitlePayExercisedYear born
Mr. Chi Keung To ACGI, B.Sc., M.B.A.Executive Chairman68.3kN/A1951
Dr. Wei-Guo Su B.Sc., Ph.D.CEO, Chief Scientific Officer & Executive Director1.97MN/A1959
Mr. Chig Fung Cheng BEc, CACFO & Executive Director773.06kN/A1967
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.ECompany Secretary & Non-Executive DirectorN/AN/A1952
Dr. Karen Jane AtkinExecutive VP & COON/AN/A1966
David NgHead of Investor Relations & Capital StrategiesN/AN/AN/A
Mr. Charles George Rupert NixonGroup General CounselN/AN/A1970
Mr. Kin Hung Lee M.B.A.Senior Vice President of Corporate Management & CommunicationsN/AN/A1977
Ms. Selina ZhangSenior Vice President of Global Human ResourcesN/AN/AN/A
Dr. Qingmei Wang Ph.D.Senior Vice President of Business Development & Strategic AlliancesN/AN/A1963
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Corporate governance

Hutchison China MediTech Limited’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.